Search Results - "Kroger, L A"

Antibody Responses to Macrocycles in Lymphoma by DeNardo, G.L, Mirick, G.R, Kroger, L.A, O'Donnell, R.T, Meares, C.F, DeNardo, S.J

“…Metallic radioimmunoconjugates have promise for radioimmunoimaging and therapy. Macrocyclic chelating agents allow formation of stable metallic…”
Get full text

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia by DeNardo, Gerald L., Lamborn, Kathleen R., Goldstein, Desirée S., Kroger, Linda A., DeNardo, Sally J.

“…BACKGROUND Because most patients with advanced non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the…”
Get full text

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts by DeNardo, G L, Kroger, L A, Meares, C F, Richman, C M, Salako, Q, Shen, S, Lamborn, K R, Peterson, J J, Miers, L A, Zhong, G R, DeNardo, S J

“…Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast cancer. To enhance this potential, a novel ChL6 immunoconjugate that is…”
Get full text

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies by LAMBORN, K. R, DENARDO, G. L, DENARDO, S. J, GOLDSTEIN, D. S, SHEN, S, LARKIN, E. C, KROGER, L. A

“…This study was designed to evaluate dosimetric, pharmacokinetic, and other treatment-related parameters as predictors of outcome in patients with advanced…”
Get full text

Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3) by DeNardo, G L, Kroger, L A, DeNardo, S J, Miers, L A, Salako, Q, Kukis, D L, Fand, I, Shen, S, Renn, O, Meares, C F

“…BrE-3 is monoclonal antibody that has promise for imaging and therapy of human adenocarcinoma. Because of observations in therapeutic trials of yttrium-90…”
Get more information

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma by DeNardo, G L, DeNardo, S J, Goldstein, D S, Kroger, L A, Lamborn, K R, Levy, N B, McGahan, J P, Salako, Q, Shen, S, Lewis, J P

“…Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when…”
Get more information

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy by DeNardo, S J, Burke, P A, Leigh, B R, O'Donnell, R T, Miers, L A, Kroger, L A, Goodman, S L, Matzku, S, Jonczyk, A, Lamborn, K R, DeNardo, G L

“…Radioimmunotherapy (RIT) has been hampered by delivery of only a small fraction of the administered dose of radiolabeled MAb to tumor. A strategy for creating…”
Get more information

The biologic window for chimeric L6 radioimmunotherapy by DeNardo, S J, Mirick, G R, Kroger, L A, O'Grady, L F, Erickson, K L, Yuan, A, Lamborn, K R, Hellstrom, I, Hellstrom, K E, DeNardo, G L

“…There has been little success in using radioimmunotherapy in patients with adenocarcinoma, partly because of the low tumor uptake of the administered…”
Get more information

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma by DeNardo, Sally J., Kroger, Linda A., Lamborn, Kathleen R., Miers, Laird A., O'Donnell, Robert T., Kukis, David L., Richman, Carol M., DeNardo, Gerald L.

“…BACKGROUND The beneficial effects of radioimmunotherapy (RIT) may result from activation of molecular pathways that lead to programmed cell death (apoptosis)…”
Get full text

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol by Denardo, S J, Richman, C M, Kukis, D L, Shen, S, Lamborn, K R, Miers, L A, Kroger, L A, Perez, E A, Denardo, G L

“…Paclitaxel (Taxol) has demonstrated synergistic enhancement of radioimmunotherapy (RIT) of breast cancer with Y-90 labeled antibody ChL6, in the xenografted…”
Get more information

L6 monoclonal antibody binds prostate cancer by O'Donnell, Robert T., DeNardo, Sally J., Shi, Xu-Bao, Mirick, Gary R., DeNardo, Gerald L., Kroger, Linda A., Meyers, Frederick J.

“…BACKGROUND Radioimmunotherapy (RIT) is a promising new modality for targeted, systemic delivery of radionuclides specifically to sites of androgen‐independent…”
Get full text

Radioimmunolocalization of Metastatic Breast Carcinoma Using Indium-111-Methyl Benzyl DTPA BrE-3 Monoclonal Antibody: Phase I Study by Kramer, Elissa Lipcon, DeNardo, Sally J, Liebes, Leonard, Kroger, Linda A, Noz, Marilyn E, Mizrachi, Howard, Salako, Qansy A, Furmanski, Philip, Glenn, Stephan D, DeNardo, Gerald L, Ceriani, Roberto

“…Pharmacokinetics of radiolabeled BrE3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast…”
Get full text

Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody by DeNardo, S J, Kroger, L A, MacKenzie, M R, Mirick, G R, Shen, S, DeNardo, G L

“…A patient with aggressive, chemotherapy-resistant non-Hodgkins lymphoma (NHL) was treated with 131I-Lym-1, a mouse antibody, on a protocol designed for serial…”
Get more information

A new era for radiolabeled antibodies in cancer? by DeNardo, Sally J, Kroger, Linda A, DeNardo, Gerald L

“…Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3–50-times higher than…”
Get full text

Milestones in the development of Lym-1 therapy by DeNardo, G L, O'Donnell, R T, Rose, L M, Mirick, G R, Kroger, L A, DeNardo, S J

“…Lym-1, a monoclonal antibody (MAb) that preferentially targets malignant lymphocytes, has induced therapeutic remissions in patients with advanced…”
Get more information

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma by O'Donnell, R T, Leigh, B R, Christensen, S D, Goldstein, D S, Kukis, D L, Shen, S, Yuan, A, DeNardo, D A, Kroger, L A, DeNardo, G L

“…Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because…”
Get more information

Synergy of Taxol and Radioimmunotherapy with Yttrium-90-Labeled Chimeric L6 Antibody: Efficacy and Toxicity in Breast Cancer Xenografts by DeNardo, Sally J., Kukis, David L., Kroger, Linda A., Robert T. O' Donnell, Lamborn, Kathleen R., Miers, Laird A., DeNardo, David G., Meares, Claude F., DeNardo, Gerald L.

“…Synergistic multimodality therapy is needed for breast cancer. Breast cancer frequently has p53 mutations that result in cells less likely to undergo apoptosis…”
Get full text

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody by Denardo, S J, O'Grady, L F, Richman, C M, Goldstein, D S, O'Donnell, R T, Denardo, D A, Kroger, L A, Lamborn, K R, Hellström, K E, Hellström, I, Denardo, G L

“…The biologically active, antiadenocarcinoma monoclonal antibody chimeric L6 (ChL6) was labeled with 131I and administered in cycles to patients with metastatic…”
Get more information

Radiation Dosimetry for 90Y-2IT-BAD-Lym-1 Extrapolated from Pharmacokinetics Using 111In-2IT-BAD-Lym-1 in Patients with Non-Hodgkin's Lymphoma by DeNardo, Gerald L, O'Donnell, Robert T, Shen, Sui, Kroger, Linda A, Yuan, Aina, Meares, Claude F, Kukis, David L, DeNardo, Sally J

“…Several monoclonal antibodies, including Lym-1, have proven effective for treatment of hematologic malignancies. Lym-1, which preferentially targets malignant…”
Get full text

New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor by Feng, X, Pak, R H, Kroger, L A, Moran, J K, DeNardo, D G, Meares, C F, DeNardo, G L, DeNardo, S J

“…Monoclonal antibodies were raised against yttrium(III)-1, 4, 7, 10-tetraazacyclododecane-N,N',N''N'''--tetraacetic acid (Y-DOTA) and copper(II)-1, 4, 8,…”
Get more information